CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. The Company's two key clinical development candidates are Seladelpar and Arhalofenate. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and the epidemic in nonalcoholic SteatoHepatitis. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. The Company's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

Type
Public
HQ
Newark, US
Founded
1991
Size (employees)
21 (est)
CymaBay Therapeutics was founded in 1991 and is headquartered in Newark, US
Report incorrect company information

Key People/Management at CymaBay Therapeutics

Sujal Shah

Sujal Shah

President and Chief Executive Officer
Pol Boudes M.D

Pol Boudes M.D

Chief Medical Officer
Robert L. Martin Ph.D

Robert L. Martin Ph.D

Senior Vice President, Manufacturing and Nonclinical Development
Klara Dickinson

Klara Dickinson

Senior Vice President, Regulatory Affairs and Quality Assurance
Charles A. McWherter Ph.D

Charles A. McWherter Ph.D

Senior Vice President and Chief Scientific Officer
Patrick J. OMara

Patrick J. OMara

Senior Vice President, Business Development
Show more

CymaBay Therapeutics Office Locations

CymaBay Therapeutics has an office in Newark
Newark, US (HQ)
7999 Gateway Blvd
Show all (1)
Report incorrect company information

CymaBay Therapeutics Financials and Metrics

CymaBay Therapeutics Financials

USD

Net income (Q1, 2018)

(17 m)

EBIT (Q1, 2018)

(12.9 m)

Market capitalization (22-Jun-2018)

807.5 m

Closing share price (22-Jun-2018)

13.7

Cash (31-Mar-2018)

65.6 m
CymaBay Therapeutics's current market capitalization is $807.5 m.
Annual
USDFY, 2017

General and administrative expense

12.4 m

R&D expense

18.9 m

Operating expense total

31.3 m

EBIT

(21.3 m)
Quarterly
USDQ1, 2018

General and administrative expense

3.4 m

R&D expense

9.5 m

Operating expense total

12.9 m

EBIT

(12.9 m)
Annual
USDFY, 2017

Cash

23.1 m

Current Assets

103.5 m

PP&E

69 k

Total Assets

104.2 m
Quarterly
USDQ1, 2018

Cash

65.6 m

Current Assets

231.2 m

PP&E

103 k

Total Assets

232.3 m
Annual
USDFY, 2017

Net Income

(27.6 m)

Depreciation and Amortization

35 k

Accounts Payable

412 k

Cash From Operating Activities

(19.6 m)
Quarterly
USDQ1, 2018

Net Income

(17 m)

Depreciation and Amortization

12 k

Accounts Payable

727 k

Cash From Operating Activities

(6.4 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information